Commentary
Video
Author(s):
D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses ongoing research for patients with non–small cell lung cancer who harbor NRG1 fusions.
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer
Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC
FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS